Salidroside facilitates therapeutic angiogenesis in diabetic hindlimb ischemia by inhibiting ferroptosis

Biomed Pharmacother. 2023 Mar:159:114245. doi: 10.1016/j.biopha.2023.114245. Epub 2023 Jan 12.

Abstract

Hindlimb ischemia (HLI), in which blood perfusion to the hindlimb is obstructed, is one of the major complications of diabetes. Skeletal muscle cells are crucial for revascularization as they can secrete various angiogenic factors; however, hyperglycemia impairs their viability and subsequently their angiogenic potential. Salidroside can promote skeletal muscle cell viability under hyperglycemia; however, the molecular mechanism is still poorly understood. Here we revealed that salidroside could suppress hyperglycemia-induced ferroptosis in skeletal muscle cells by promoting GPX4 expression, thereby restoring their viability and paracrine functions. These in turn promoted the proliferation and migration potentials of blood vessel-forming cells. Furthermore, we showed that salidroside/GPX4-mediated ferroptosis inhibition is crucial for promoting angiogenesis and blood perfusion recovery in diabetic HLI mice. Together, we reveal a novel molecular mechanism of salidroside in enhancing skeletal muscle cells-mediated revascularization and blood perfusion recovery in diabetic HLI mice, further highlighting it as a potential compound for treating diabetic HLI.

Keywords: Diabetic HLI; Ferroptosis; Salidroside; Skeletal muscle cells; Therapeutic angiogenesis.

MeSH terms

  • Animals
  • Diabetes Mellitus*
  • Disease Models, Animal
  • Ferroptosis*
  • Hindlimb / metabolism
  • Hyperglycemia*
  • Ischemia / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Skeletal / metabolism
  • Neovascularization, Physiologic

Substances

  • rhodioloside